Editor Message
(Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - February 23, 2017 Category: Cardiology Source Type: research
Guidelines for Authors
(Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - February 23, 2017 Category: Cardiology Source Type: research
Shorter Door-To-Balloon ST-Elevation Myocardial Infarction Time: Should There Be a Minimum Limit?
In ST-elevation myocardial infarction (STEMI) ischemic time is directly related to permanent myocardial damage and mortality. Therefore, it is crucial to restore myocardial perfusion rapidly. Door-to-balloon (DTB) time is defined as the duration between the arrival time of the patient to the medical facility until the time he or she is treated with percutaneous coronary intervention. Currently, DTB is the criterion that measures the quality of care provided to patients with STEMI at any given institution. (Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - February 23, 2017 Category: Cardiology Authors: Sameh Askandar, Tamunoinemi Bob-Manuel, Pahul Singh, Rami N. Khouzam Source Type: research
Shorter Door-To-Balloon STEMI Time: Should there be a Minimum Limit?
In ST-elevation myocardial infarction (STEMI) ischemic time is directly related to permanent myocardial damage and mortality. Therefore, it is crucial to restore myocardial perfusion rapidly. Door to balloon (DTB) time is defined as the duration between the arrival time of the patient to the medical facility until the time he/she is treated with percutaneous coronary intervention (PCI). Currently, DTB is the criterion that measures the quality of care provided to patients with STEMI at any given institution. (Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - February 22, 2017 Category: Cardiology Authors: Sameh Askandar, Tamunoinemi Bob-Manuel, Pahul Singh, Rami N. Khouzam Source Type: research
Foreword
Antiplatelet therapy is a very important component of the management of patients who are at risk of secondary vascular disease. Low dose aspirin is the most utilized antiplatelet therapy and it is the most effective. However, it has been associated with risk of gastrointestinal toxicity, leading patients to discontinue therapy and increasing their cardiovascular risk. In patients with high risk of gastrointestinal events with aspirin, the use of proton pump inhibitors is presently recommended. These agents are effective in reducing the gastrointestinal adverse events associated with aspirin therapy and in addition their ut...
Source: Current Problems in Cardiology - February 1, 2017 Category: Cardiology Source Type: research
Upper Gastrointestinal Toxicity Associated with Long-Term Aspirin Therapy: Consequences and Prevention
Antiplatelet therapy represents a fundamental part of preventive management for patients who are at risk of a secondary cardiovascular disease (CVD) event. In most cases, the antiplatelet regimen is based on low-dose aspirin, a drug that is highly effective in reducing the incidence of CVD events, but is associated with a substantial risk of gastrointestinal (GI) toxicity. The dyspeptic symptoms which can result from aspirin administration, and which may occur with or without associated ulceration and bleeding, may lead patients to discontinue therapy, thus increasing their CVD risk. (Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - January 31, 2017 Category: Cardiology Authors: Carl J Lavie, Colin W. Howden, James Scheiman, James Tursi Source Type: research
Renal Artery Stenosis: When to Revascularize in 2017
Atherosclerotic renal artery stenosis is the leading cause of secondary hypertension; it can also cause progressive renal insufficiency and cardiovascular complications such as refractory heart failure and flash pulmonary edema. Medical therapy including risk factor modification, renin-angiotensin-aldosterone system antagonists, lipid lowering agents and antiplatelet therapy is the first line of treatment in all patients. Patients with uncontrolled renovascular hypertension despite optimal medical therapy, ischemic nephropathy and cardiac destabilization syndromes who have severe renal artery stenosis are likely to benefit...
Source: Current Problems in Cardiology - January 19, 2017 Category: Cardiology Authors: Jose D. Tafur, Christopher J. White Source Type: research
Editorial Board
(Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - January 17, 2017 Category: Cardiology Source Type: research
Title Page
(Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - January 17, 2017 Category: Cardiology Source Type: research
Information for Readers
(Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - January 17, 2017 Category: Cardiology Source Type: research
Table of Contents
(Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - January 17, 2017 Category: Cardiology Source Type: research
Foreword
Atherosclerotic renal artery stenosis is not only the leading cause of secondary hypertension but also can cause progressive renal insufficiency and cardiovascular complications such as refractory heart failure and flash pulmonary edema. The management of these patients include, risk factor modification, renin-angiotensin-aldosterone system antagonists, lipid lowering agents and antiplatelet therapy. The patients that remained hypertensive despite medical therapy as well as patients with ischemic nephropathy and heart failure and have severe renal artery stenosis will likely to benefit from renal artery revascularization. ...
Source: Current Problems in Cardiology - January 16, 2017 Category: Cardiology Source Type: research
Foreword
Rheumatic fever has historically been the most common cause of mitral stenosis. However, its prevalence has declined significantly in the developed world with the wide spread use of antibiotics. In addition, mitral stenosis was the first valvular pathology treated with surgical techniques. Rheumatic mitral stenosis, because of its historical abundance, has been studied extensively. In fact, majority of evidence regarding imaging and management of mitral stenosis has derived from studies on patients with rheumatic mitral stenosis. (Source: Current Problems in Cardiology)
Source: Current Problems in Cardiology - January 9, 2017 Category: Cardiology Source Type: research
Echocardiographic Assessment of Degenerative Mitral Stenosis: A Diagnostic Challenge of an Emerging Cardiac Disease
Degenerative mitral stenosis (DMS) is characterized by decreased mitral valve (MV) orifice area and increased transmitral pressure gradient (TMPG) due to chronic non-inflammatory degeneration and subsequent calcification of the fibrous mitral annulus and the MV leaflets. The ‘true’ prevalence of DMS in the general population is not well known. DMS predominantly affects elderly individuals, many of whom have multiple other comorbidities. Transcatheter MV replacement techniques, although their long-term outcomes are to be tested, have been gaining popularity and may e merge as an optimal treatment options for patients wi...
Source: Current Problems in Cardiology - January 9, 2017 Category: Cardiology Authors: Ahmet Af şin Oktay, Yvonne E. Gilliland, Carl J. Lavie, Stephen R. Ramee, Sangeeta Shah, Michael E. Cash, Homeyar Dinshaw, Salima Qamruddin Source Type: research
Procedural Variations in Performing Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction
Multiple variations exist in performing a primary percutaneous coronary intervention (pPCI) in ST-segment elevation myocardial infarction (STEMI) amongst various cardiologists. These variations range from the choice of peripheral access artery (radial vs. femoral), performance/time of complete angiography including left ventriculography (LVgraphy), and non-culprit vessel angiography prior to or after intervening on the culprit vessel. The reasons for such variations include; emphasis on door-to-balloon (DTB) time, knowledge of cardiac anatomy prior to proceeding with pPCI, physician expertise, and the level of comfort with...
Source: Current Problems in Cardiology - December 21, 2016 Category: Cardiology Authors: Radhika M. Mehta, Manyoo Agarwal, Ikechukwu Ifedili, Wael W. Rizk, Rami N. Khouzam Source Type: research
